GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2007

Argos Licenses T-Cell Technology to Therakos

  • Argos Therapeutics signed an exclusive licensing agreement with Therakos, a Johnson & Johnson company, for the research and development of new treatments based on Argos’ regulatory T-cell technology.

    Argos is actively developing immunotherapies or indications such as cancer, infectious diseases, autoimmune disorders,  and transplantation using its Arcelis technology, which trains the immune system to recognize and attack the disease.

    “The licensing agreement with Therakos will enable accelerated development of an asset outside our primary focus, while providing Argos with nondilutive financial resources,” said John Bonfiglio, Ph.D., president and CEO at Argos Therapeutics. “This transaction further demonstrates our ability to leverage Argos´ leading immunotherapy science both through our own programs as well as through collaborations with select corporate partners."


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »